145 related articles for article (PubMed ID: 11721066)
1. Palivizumab.
Gupta D; Gupta P
Indian Pediatr; 2001 Nov; 38(11):1265-9. PubMed ID: 11721066
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Mahadevia PJ; Malinoski FJ
Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
[No Abstract] [Full Text] [Related]
3. [Prevention of respiratory syncytial virus infections with palivizumab].
Ellingsen BB; Aase SA; Øymar K
Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
[No Abstract] [Full Text] [Related]
4. Palivizumab prophylaxis: how to compare pre- and post-prophylaxis eras?
Korppi M
Pediatr Pulmonol; 2007 Jul; 42(7):660; author reply 661. PubMed ID: 17534973
[No Abstract] [Full Text] [Related]
5. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
Fitzgerald DA
Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
[TBL] [Abstract][Full Text] [Related]
6. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
Danés Carreras I; Arnau De Bolós JM
An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
[No Abstract] [Full Text] [Related]
7. [Guidelines for respiratory syncytial virus prophylaxis. An update].
Carbonell-Estrany X; Quero Jiménez J
An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
[TBL] [Abstract][Full Text] [Related]
8. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks.
Resch B; Gusenleitner W; Müller WD; Haas J
Eur J Clin Microbiol Infect Dis; 2006 Feb; 25(2):120-2. PubMed ID: 16491302
[No Abstract] [Full Text] [Related]
9. [Infections with RS viruses in children].
Krankenpfl J; 2004; 42(7-10):231. PubMed ID: 15675393
[No Abstract] [Full Text] [Related]
10. Palivizumab for prophylaxis of RSV infection: five epidemic seasons' experience on adverse effects (2002-2007).
Parmigiani S; Pezzoni S; Solari E; Arena V; De Martino A; Alessandrini C; Moretti S; Bevilacqua G
J Perinat Med; 2009; 37(3):304-5. PubMed ID: 19196216
[No Abstract] [Full Text] [Related]
11. The effect of an interventional program on adherence to the american academy of pediatrics guidelines for palivizumab prophylaxis.
Afghani B; Ngo T; Leu SY; Wu FL; Cecilio M; Aron-Johnson P; Zeitany R; Sills J; Amin A
Pediatr Infect Dis J; 2006 Nov; 25(11):1019-24. PubMed ID: 17072124
[TBL] [Abstract][Full Text] [Related]
12. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.
Zhao X; Chen FP; Sullender WM
Virology; 2004 Jan; 318(2):608-12. PubMed ID: 14972528
[TBL] [Abstract][Full Text] [Related]
13. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting.
Manzoni P; Leonessa M; Farina D; Gomirato G
Pediatr Transplant; 2007 Jun; 11(4):456-7. PubMed ID: 17493231
[No Abstract] [Full Text] [Related]
16. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
[TBL] [Abstract][Full Text] [Related]
17. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
[No Abstract] [Full Text] [Related]
18. Palivizumab and RSV prevention.
Lenney W
Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960342
[No Abstract] [Full Text] [Related]
19. Palivizumab and RSV prevention.
Carnegie C
Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960341
[No Abstract] [Full Text] [Related]
20. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody.
DeVincenzo JP; Aitken J; Harrison L
J Pediatr; 2003 Jul; 143(1):123-6. PubMed ID: 12915838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
